Our results are comparable to the world leaders in proton therapy in the US and Japan.
Our physicians’ experience, our technology, excellent results and professional attitude give you the maximum chance of being cured.
Proton radiotherapy has minimal toxicity (side effects). Recently published studies describe serious adverse effects of treatment in less than 1% in a large population of patients.
Proton radiotherapy is a fully outpatient treatment and does not require sick leave in most cases. Due to the possibility of very precise targeting of the proton beam directly to the tumour in the prostate, we can protect the healthy tissues in its vicinity. Their unwanted exposure to radiation increases the risk of side effects. Thanks to proton radiotherapy, we are able to significantly reduce radiation doses to the bladder, bulb of penis, and rectum, therefore, in most cases, patients do not suffer from incontinence, impotence and intestinal problems. In addition, for high-risk prostate cancer, proton radiotherapy allows us to irradiate pelvic lymph nodes, which have a high probability of subclinical involvement; if these lymph nodes are not removed during surgery or irradiated, the risk of disease recurrence increases significantly. For low- and medium-risk prostate cancer, stereotactic radiation can be used, where the treatment period lasts 5 working days and radiation is administered every other day. For high-risk disease, the treatment period is 21 working days, and radiation is administered every working day.
It is apparent that the proton beam irradiates only the target volume (prostate area), i.e., the radiation is targeted almost exclusively only at the tissue which is affected. On the contrary, photon radiation, owing to its physical properties, significantly affects also the surrounding healthy structures in the abdominal cavity.
According to the latest published data of the Proton Center in Prague, the probability of cure measured as five-year survival without PSA relapse is:
96.5% for low-risk prostate cancer,
93.7% for favourable medium-risk prostate cancer
91.2% for unfavourable medium-risk prostate cancer
and 75-85% for high-risk prostate cancers.
